10x Genomics: Still Waiting For Entry

Yuichiro Chino/Moment via Getty Images In my previous article on 10x Genomics (NASDAQ:TXG), I debated the potential insertion of TXG in the Compounding Healthcare "Bio Boom" speculative portfolio. This deliberation was centered on the company's ability to develop cutting-edge products, services, and R&D capabilities. The article defined my game plan fixated on technical analysis and explicit conditions for entry. However, those circumstances did not appear, and I am still sitting on the sidelines, awaiting ...